STOCKHOLM, SWEDEN, - September 29, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today the publication of a collaborative scientific project with the Swiss Institute of Allergy and Asthma Research (SIAF) in Davos, Switzerland. The study is the first to use Nevisense to measure skin barrier function in human excised skin samples, demonstrating Nevisense as an effective laboratory research device.

STOCKHOLM, SWEDEN, - September 28 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today the publication of the clinical results from a study performed together with the University Children's Hospital Zürich. The study demonstrates the ability of Nevisense to distinguish children with and without Atopic Dermatitis (AD).

STOCKHOLM, SWEDEN, - September 25, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that they have entered into a collaboration agreement with Bare Dermatology to pilot Nevisense in select locations in Texas. Bare Dermatology is a dermatology practice group in the Greater Dallas area, with five offices and a team of nationally renowned dermatologists. The agreement will provide Bare Dermatology with Nevisense, the only FDA-approved test for early melanoma detection at point-of-care.